^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BMS-986226
i
Other names: BMS-986226, BMS 986226, BMS986226
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS
Drug class:
ICOS agonist
Related drugs:
over1year
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=80, Terminated, Bristol-Myers Squibb | Completed --> Terminated; Study CA021-002 was terminated because the Sponsor discontinued further development of BMS-986226 due to a change in business objectives. The decision for the study closure was not related to any safety concerns associated with BMS-986226.
Trial termination • Combination therapy • IO biomarker • Metastases
|
ICOS (Inducible T Cell Costimulator)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986226
Share via
